Financial Performance - For the year ended December 31, 2025, SCYNEXIS reported total revenue of $20.6 million, a significant increase from $3.7 million in 2024, primarily due to the GSK license agreement [8] - The company recognized a cumulative catch-up of $17.2 million in license agreement revenue associated with the Binding 2025 MOU with GSK [8] - Research and development expenses decreased to $22.3 million in 2025 from $26.4 million in 2024, a reduction of 15.6% [9] - Selling, general and administrative expenses slightly decreased to $14.4 million in 2025 from $14.5 million in 2024 [10] - The net loss for 2025 was $8.6 million, compared to a net loss of $21.3 million in 2024, indicating improved financial performance [18] Cash Position - As of December 31, 2025, SCYNEXIS had cash, cash equivalents, and investments totaling $56.3 million, down from $75.1 million in 2024 [12] - The company received a one-time non-refundable payment of $24.8 million from GSK in Q4 2025, extending its cash runway for more than two years [5][12] Product Development - SCYNEXIS is advancing its second-generation fungicide, SCY-247, with the first patient dosed in a Phase 1 study of the intravenous formulation, and topline data expected in the second half of 2026 [5][6] - The company plans to initiate an expanded access program for SCY-247 in the first half of 2026 to address patient needs for alternative antifungal therapies [5][6] - The FDA granted SCY-247 Qualified Infectious Disease Product (QIDP) and Fast Track Designations, which may facilitate its development and approval process [6] Strategic Partnerships - SCYNEXIS completed the transfer of the BREXAFEMME (ibrexafungerp) New Drug Application to GSK, which is committed to relaunching the product [6] - Following the relaunch of BREXAFEMME, SCYNEXIS could receive up to $145.5 million in annual net sales milestones and low to mid-single digit royalties [6] Research Initiatives - A novel series of antifungal compounds from SCYNEXIS' proprietary triterpenoid antifungal platform received funding through a federal grant, establishing a Center of Excellence in Translational Research [7]

Core Insights - SCYNEXIS, Inc. has initiated a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial for its intravenous formulation of SCY-247, an antifungal therapy aimed at treating invasive candidiasis and preventing invasive fungal diseases, with results expected in 2026 [1][2] Group 1: Company Developments - The first participants have been dosed in the Phase 1 trial of SCY-247, which has received both Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA, indicating its potential significance in treating severe fungal infections [2][3] - SCY-247's oral formulation has shown positive results in previous SAD/MAD data, demonstrating excellent pharmacokinetic and pharmacodynamic properties, achieving target exposures at lower doses than first-generation antifungals [2] - The company is exploring non-dilutive funding opportunities to support the SCY-247 program, highlighting its commitment to addressing health security threats posed by antifungal resistance [2] Group 2: Product Information - SCY-247 is part of SCYNEXIS's proprietary antifungal platform "fungerps," which includes Ibrexafungerp, already approved for treating vulvovaginal candidiasis [4] - The second-generation fungerp SCY-247 is currently in clinical development stages, with additional antifungal assets from this class in pre-clinical and discovery phases [4]

Core Viewpoint - SCYNEXIS, Inc. has resumed patient dosing in the Phase 3 MARIO study for oral ibrexafungerp, a potential treatment for invasive candidiasis, after the FDA lifted a clinical hold due to manufacturing concerns [1][2]. Group 1: Study Resumption and Financial Implications - The Phase 3 MARIO study aims to evaluate ibrexafungerp as a step-down therapy from IV echinocandins for invasive candidiasis, a serious infection [1]. - The resumption of dosing triggers a $10 million milestone payment from GSK, with an additional $20 million payment due six months after dosing begins; however, there is a dispute between SCYNEXIS and GSK regarding these payments [1][6]. - Approximately 25% of the projected patients have already been enrolled in the study, indicating strong interest from the scientific community [2]. Group 2: Need for New Treatment Options - There is a significant unmet need for new antifungal treatments, particularly for Candida strains resistant to existing therapies [3]. - Experts emphasize the importance of ibrexafungerp in improving outcomes for patients with life-threatening invasive fungal infections [3]. Group 3: About Ibrexafungerp and Triterpenoid Antifungals - Ibrexafungerp is the first in a new class of triterpenoid antifungals, which are glucan synthase inhibitors with both oral and IV formulations, showing broad-spectrum activity against multidrug-resistant pathogens [4]. - Ibrexafungerp is already approved in the U.S. for vulvovaginal candidiasis and is in late-stage development for invasive candidiasis [4][7].